UBE2S is associated with malignant characteristics of breast cancer cells

Fang

et al. 2020

Preprint

Background Renal cell cacinoma (RCC) accounts for 3% of human cancers, and clear cell renal cell carcinoma (ccRCC) is the most common pathological type of RCC. Cell surface proteins have been shown to play an important role in the occurrence and progression of various cancers. In this study, we focused on plasma membrane proteins (PMPs), to explore their potential value in ccRCC. Methods The PMPs expression profiles and ccRCC patients’ clinical information were downloaded from TCGA database. Through a series of bioinformatic methods, we established a plasma membrane proteins prognostic model. Results Multivariate cox regression analysis and area under receiver operating characteristic curve indicated that this model was an effective independent predictor of ccRCC clinical outcomes. Combined with other two clinical characteristics, a nomogram was constructed to predict patient survival at 1, 3, and 5 years. Conclusions Our study is the first to explore the prognostic value of plasma membrane proteins in clear cell renal cell carcinoma. We hope our work could provide a new viewpoint for ccRCC prognosis and drawn people’s attention to plasma membrane proteins in clear cell renal cell carcinoma.

Section: Discussionmentioning

confidence: 70%

A plasma membrane protein based prognostic model in clear cell renal cell carcinoma

Fang

et al. 2020

Preprint

“…Although there are few studies on the roles of UBE2S and UBE2V2 in OC, both genes are involved in the occurrence and progression of other tumors. UBE2S was reported to be aberrantly expressed in some gynecological tumors, including breast, cervical, and endometrial cancer, and its knockdown inhibits the proliferation of cancer cells and promotes apoptosis [45][46][47]. UBE2V2 overexpression seems to be involved in the pathogenesis of gastric cancer, and is signi cantly associated with poor prognosis in ERpositive/HER2-negative breast cancer [48,49].…”

Section: Discussionmentioning

confidence: 99%

Increased Expression of UBE2T Predicting Poor Survival of Ovarian Cancer: Based on Comprehensive Analysis of UBE2s, Clinical Samples And the GEO Database

Zou

et al. 2020

Preprint

Background：Ubiquitin-conjugating enzymes E2 (UBE2) have been reported in the microenvironment of various malignant tumors, but their correlation with ovarian cancer remains elusive. Methods: The Oncomine, GEPIA, Kaplan-Meier Plotter, cBioPortal, and STRING databases were used to systematically analyze the expression pattern, prognostic value, genetic variation, and biological function of 12 members of the UBE2 gene family in ovarian cancer. UBE2T exhibited the greatest correlation with ovarian cancer and was thus further examined. Gene set enrichment analysis (GSEA), as well as analyses of function and pathway enrichment, somatic mutations, copy number variation, and methylation were performed, and the correlation with immune cell infiltration was examined to explore the mechanism underlying aberrant UBE2T expression. Finally, the expression and prognostic value of UBE2T in ovarian cancer were verified by immunohistochemical evaluation of 131 clinical ovarian samples and the Gene Expression Omnibus (GEO) database (GSE51088, GSE73614, and GSE63885 datasets) analysis.Results: The mRNA levels of UBE2C, UBE2N, UBE2S, and UBE2T were significantly upregulated in ovarian cancer compared with those in normal ovarian tissue. In patients with ovarian serous carcinoma, UBE2A, UBE2B, UBE2C, UBE2G, and UBE2T upregulation and UBE2R2 downregulation were associated with poor overall survival. Moreover, UBE2A, UBE2N, and UBE2T upregulation and UBE2G and UBE2R2 downregulation were associated with poor progression-free survival. Immunohistochemistry revealed that UBE2T was significantly upregulated in ovarian malignant tumors compared with that in borderline tumors, benign tumors, and normal ovarian tissues, and its high expression was associated with poor prognosis. The Cox model showed that UBE2T upregulation was an independent risk factor affecting the prognosis of ovarian cancer (hazard ratio: 4.095, P=0.029). The above results were verified in the GEO database. In addition, UBE2T was associated with specific immune cells and mainly involved in cell cycle-related events. Genomic analysis showed that TP53 and TTN mutations were associated with UBE2T expression. Gene copy number amplification and hypomethylation may be responsible for UBE2T upregulation in ovarian cancer. Conclusions: UBE2 family members may play a role in the development of ovarian cancer. Specifically, UBE2T could serve as a new prognostic marker and therapeutic target for this disease.

“…Although there are few studies on the roles of UBE2S and UBE2V2 in OC, both genes are involved in the occurrence and progression of other tumors. UBE2S was reported to be aberrantly expressed in some gynecological tumors, including breast, cervical, and endometrial cancer, and its knockdown inhibits the proliferation of cancer cells and promotes apoptosis [45][46][47]. UBE2V2 overexpression seems to be involved in the pathogenesis of gastric cancer, and is signi cantly associated with poor prognosis in ER-positive/HER2negative breast cancer [48,49].…”

Section: Discussionmentioning

confidence: 99%

Increased expression of UBE2T predicting poor survival of ovarian cancer: based on comprehensive analysis of UBE2s, clinical samples and the GEO database

Zou

et al. 2020

Preprint

Background： Ubiquitin-conjugating enzymes E2 (UBE2) have been reported in the microenvironment of various malignant tumors, but their correlation with ovarian cancer remains elusive.Methods: The Oncomine, GEPIA, Kaplan-Meier Plotter, cBioPortal, and STRING databases were used to systematically analyze the expression pattern, prognostic value, genetic variation, and biological function of 12 members of the UBE2 gene family in ovarian cancer. UBE2T exhibited the greatest correlation with ovarian cancer and was thus further examined. Gene set enrichment analysis (GSEA), as well as analyses of function and pathway enrichment, somatic mutations, copy number variation, and methylation were performed, and the correlation with immune cell infiltration was examined to explore the mechanism underlying aberrant UBE2T expression. Finally, the expression and prognostic value of UBE2T in ovarian cancer were verified by immunohistochemical evaluation of 131 clinical ovarian samples and the Gene Expression Omnibus (GEO) database (GSE51088, GSE73614, and GSE63885 datasets) analysis.Results: The mRNA levels of UBE2C , UBE2N , UBE2S , and UBE2T were significantly upregulated in ovarian cancer compared with those in normal ovarian tissue. In patients with ovarian serous carcinoma, UBE2A , UBE2B , UBE2C , UBE2G , and UBE2T upregulation and UBE2R2 downregulation were associated with poor overall survival. Moreover, UBE2A , UBE2N , and UBE2T upregulation and UBE2G and UBE2R2 downregulation were associated with poor progression-free survival. Immunohistochemistry revealed that UBE2T was significantly upregulated in ovarian malignant tumors compared with that in borderline tumors, benign tumors, and normal ovarian tissues, and its high expression was associated with poor prognosis. The Cox model showed that UBE2T upregulation was an independent risk factor affecting the prognosis of ovarian cancer (hazard ratio: 4.095, P= 0.029). The above results were verified in the GEO database. In addition, UBE2T was associated with specific immune cells and mainly involved in cell cycle-related events. Genomic analysis showed that TP53 and TTN mutations were associated with UBE2T expression. Gene copy number amplification and hypomethylation may be responsible for UBE2T upregulation in ovarian cancer.Conclusions: UBE2 family members may play a role in the development of ovarian cancer. Specifically, UBE2T could serve as a new prognostic marker and therapeutic target for this disease.